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TranscriptomicsFisher’s exact test is widely used in biomedical research, particularly in genomic proﬁle analysis. Since in
most databases, the frequency distribution of genes is right skewed, we show here that its use can lead to
excessive false-positive discoveries. We propose to apply Zelen’s exact test on a stratiﬁcation of the gene
set; this solves the false discovery problem, and should avoid misleading interpretations of lists of genes
produced by various genome-wide analysis technologies.
 2013 Elsevier Inc. All rights reserved.1. Introduction
To raise hypotheses and orient projects in biomedical research,
bioinformatic analysis of genome-wide gene or protein expression
signatures is now a standard strategy. Transcriptome and proteome
studies yield large lists of genes or proteins, the interpretation of
which reveals a far more comprehensive meaning than single gene
analysis. This interpretation currently relies upon a uniquemethod,
called gene set enrichment analysis (GSEA) [1], and different types
of statistical tests, depending on available data. Several partly over-
lapping databases of reference gene sets are available from KEGG,
GO, Biocarta, MSigDB inter alia (online methods). Together, these
databases now contain thousands (>6000) of ‘reference’ gene sets
identifying canonical metabolic pathways, signalling cascades,
molecular processes, cell components, normal and pathological bio-
logical processes, positional gene sets for human chromosomal
location, as well as computationally-predicted gene sets of microR-
NA and transcription factor targets. They also comprise a growing
number of ‘experimental’ gene sets continuously updated with
newly published studies. Now, several thousands of reports involv-
ing gene set enrichment analysis illustrate how powerfully
test-based statistics boosted data mining of massive and complex
biological data, although they critically rely upon the adequacy of
the tests null hypotheses to avoid false-positive interpretations.However, despite FDR adjustment of p-values, usual tests in GSEA
frequently yield false-positive interpretations. Here, the rationale
underlying this bias is provided and an alternative method correct-
ing the ﬂaw of Fisher’s exact (FE) test is presented.
2. Methods
Methods, algorithms, supplemental tables, ﬁgures, and refer-
ences are available in the Online supplemental ﬁle.3. Discussion
We refer below to gene, pathway, and database as item, vector,
and list of vectors, respectively. Each item is a character chain cor-
responding to the gene symbol, each vector is a text ﬁle list of
items. For this study, the reference biological databases from
KEGG, GO, Biocarta and MSigDB were converted to lists of vectors
[2] (Supplemental methods). GSEA considers genome-wide expres-
sion proﬁles, that can be seen as ranked lists of genes, each affected
with a score, such as a p-value, a correlation, or a fold change. In
many instances, only a binary score is provided: the gene is in-
cluded or not in the set. This is the case considered here. However,
our conclusions regarding False Discovery Rates hold for more
general types of data (Suppl. §-KS testing). For clarity, we call
‘assay’ (any size from a few hundred to a few thousand genes) an
experimental gene set which must be compared to a database for
interpretation. Current GSEA algorithms identify its intersection
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and then decide which matchings are signiﬁcant and which are
not [1,3–5]. When comparing two vectors of items, each vector di-
vides the population of all items into two classes: those present in
the vector and those absent. The four numbers of items that either
belong to both vectors, to only one of them, or to none form a 2  2
contingency table. Many seemingly different methods are used for
computing the p-values, but the vast majority assume as underly-
ing null hypothesis that the vectors to be tested are random sam-
ples without replacement. This implies that the number of items in
each cell of the table has a hypergeometric distribution. The corre-
sponding test is called hypergeometric or Fisher’s exact (FE) test
[3,6,7]. Hence GSEA algorithms run the FE test and, for each vector
in the database, compute a p-value as a tail probability from the
hypergeometric distribution. The p-values so obtained are then ad-
justed by a False Discovery Rate (FDR) correction to account for
multiple testing [8], prior to returning only those database vectors
whose p-values are below a given signiﬁcance threshold.
We found that the null hypothesis for the FE test is inappropri-
ate for such studies, since its prerequisite is false: database vectors
are not random samples as genes are not equally frequent in them,
more precisely the frequency distribution is clearly right skewed.
For example, the actual distribution of gene frequencies in MSigDB
C2 utterly differs from that of a simulated database with the same
size and pathway lengths, but with randomly sampled pathways
(Fig. 1a and b. This is typical of all gene databases except the posi-
tional database MSigDBs C1, in which each gene is present in only
one vector, with C1’s list of vectors covering the entire human gen-
ome (Suppl. Fig. 1). This feature deeply impacts on FE-based com-
parisons. Consider a random assay where each item of the database
is independently included in the assay with a probability propor-
tional to its actual frequency in the database (instead of equalFig. 1. Unequal gene frequencies in biological databases alter the FE test. Distributio
distribution under equal probability sampling in a simulated C2-like random database (
random assay to the actual GOBP database. The random assay is a sample of 1000 genes w
equal probability, the points are below the theoretical black line, indicating p-values large
the points are high above the theoretical black line, showing too many small p-values (
vector actually devoid of information. Values declared signiﬁcant at 5% threshold after Fprobabilities as in the hypergeometric model). Then count how
many database vectors the FE test detects as having a signiﬁcant
matching with the random assay. With MSigDB C2 and a random
assay of size 1000, that experiment typically returns over 800
pathways deemed signiﬁcant at threshold 0.01 out of the 3272 of
the database, despite the FDR adjustment. This excessive FDR re-
sults from the many genes with high frequency, which artiﬁcially
increase matching numbers as they are very likely to be present
both in the random assay and in the test vector. As a consequence,
when comparing a random assay to a database, the FE test fre-
quently returns many very low p-values (<1010) for matches that
are nevertheless biologically meaningless.
To get a more comprehensive outlook of the biases possibly
introduced by the FE test, we studied the p-value distributions un-
der different null hypotheses (of lack of information in the data)
which theoretically should generate a uniform distribution of p-
values on the interval (0,1) [9]. We applied negative log10 trans-
form to p-values and analyzed the adjustment of their empirical
distribution to the theoretical exponential distribution by plots of
the ordered p-values on log10 scale. In such plots, referred to as
‘pvplots’, a point at height h corresponds to a p-value of 10h
(Fig. 1c and d. Let p = (p(i)) be the vector of p-values obtained by
repeatedly comparing an assay to d database vectors, those p-val-
ues being ranked in increasing order. Theoretically, the empirical
distribution of p should be close to the y = x ‘pink line’, or else
the ith value log(p(i)) should be close to log(i/d). The quantities
log(p(i)) will be called ‘neg-log p-values’. The pvplots of 825 FE
test-based comparisons of random assays to the actual GOBP data-
base vectors demonstrate the aforementioned FE ﬂaws (Fig. 1c and
d. The assays are samples of 1000 genes without replacement and
either equal or unequal gene probabilities. With equal gene prob-
abilities, the points are below the theoretical black line, indicatingn of gene frequency in the actual MSigDB-C2 database (a) is different from the
b) required for FE tests. Pvplots evidence the FE test ﬂaws across comparisons of a
ithout replacement and either equal probability (c) or unequal probability (d). With
r than expected: no matching will be declared signiﬁcant. With unequal probability,
FDR): an excessive number of matchings will be declared signiﬁcant for a random
DR adjustment are in lighter shade of gray.
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icant (Fig. 1c). With unequal gene probabilities, the points are high
above the theoretical black line, showing too many small p-values:
an excessive number of matchings will be declared signiﬁcant for a
random assay actually devoid of information (Fig. 1d). Thus the use
of FE test to mine databases involving unequal gene frequencies is
prone to attribute strong statistical signiﬁcance to random
matches and therefore to support misleading biological
interpretation.
Here we propose a new testing method based on a stratiﬁcation
of items according to their frequencies. Our stratiﬁcation algorithm
groups items into a relatively small number of strata. Together, the
2  2 contingency tables of all strata form a so-called ‘three way
contingency table’, to which Zelen’s exact test (ZE) [10,11] is ap-
plied. ZE tests the independence of matching numbers condition-
ally to the strata, measuring signiﬁcance relatively to the number
of genes in the strata. As the name indicates, it is based on the cal-
culation of an exact distribution, and not on a Gaussian approxima-
tion: it is the true generalization of the FE test. The distribution of
item frequencies must be determined and items should be grouped
accordingly. For a total number of items N, and a maximal number
of classes n, our algorithm groups successive classes until the total
frequency of each group exceeds N/n, the last class clumped to the
next-to-last if its frequency is smaller than N/(2n). The number n is
here chosen by Sturges clumping method [12], and the algorithm
usually outputs less than n classes that are reasonably well bal-
anced. For ﬁve database examples, the number of genes, frequency
range, number of classes recommended by three standard clump-
ing methods, and ﬁnal number of strata formed by our algorithm
are speciﬁed in Suppl. data Table 1. To assess the performance of
our method we thus analyzed pvplots of tests comparing a random
assay, sampled without replacement and unequal probability as
previously (Fig. 1d). ZE with 2, 4, 6, 8, and 10 strata came closer
to the theoretical black line, and an optimal ﬁt was achieved for
10 strata, demonstrating that ZE consistently curbed the excessive
FDR of FE (Fig. 2a). We ﬁnally assessed the performances of our
method by testing the goodness-of-ﬁt of the uniform distribution
to p-values, expecting a good ﬁt under any situation of lack of
information. Assays were repeatedly compared to databases, con-
sidering the following 3 different conditions:Fig. 2. Stratiﬁed ZE test corrects the FDR ﬂaw of the FE test. (a) Pvplots from tests of a r
GOBP database (825 pathways). FE test neg-log p-values are marked by black dots, ZE test
Comparative performances of FE (black circles) and ZE (gray circles) tests. Pvplots of F
procedure produces less extremely small p-values, thus limiting the number of pathwa
increasing p-values for the two tests, the orders of the ﬁrst pathways showed limited dis
U/E (equal probability sampled database): both methods output quite similar p-valu
distribution. This was expected since that condition corresponds to the null hypothesi
underrate signiﬁcance (not enough small p-values). The ZE procedure performs better. –
pvplots remain way above the theoretical line: signiﬁcance is clearly exaggerated. The
theoretical exponential distribution is good. A: Actual assay or database.
 E: Equal probability sampling without replacement. For the
assay, a sample with the same size as the actual assay is drawn,
and for the database, simulated pathways are drawn with the
same sizes as in the actual database.
 U: Unequal probability sampling without replacement. Samples
are drawn without replacement, with probabilities proportional
to the frequencies of genes in the database.
Applying those conditions to the assay and to the database
yields 9 different (assay/database) pairs, for which FE and ZE tests
were used. These experiments demonstrated that the p-values
from ZE are always closer to the theoretical uniform distribution
(black line) than those from FE (Fig. 2b). Unfortunately, most path-
way-enrichment approaches so far use either the FE tests of gene
lists (Gene Ontology [13], GENMAPP [14], CHIPINFO [15], GOMIN-
ER [16], ONTO-TOOLS [17], FUNCASSOCIATE [18]), or tests of gene
ranking scores (GSEA [19], GAGE [20], PAGE [21], EASE [22], Ex-
tended-GSEA [23], and SAM-GS [24]) which for the same above
reasons, present a high FDR as well (Supplemental data §-KS test-
ing). More exhaustive reviews of GSEA methods can be found in
Rivals et al. [3] already cited, and Huang et al. [25]. The latter ref-
erence lists 68 pathway-enrichment tools, all essentially based
upon the equal probability of genes as a null hypothesis. The most
widely used statistical methods in these tools are Fisher’s exact
test, Hypergeometric, Chi-squared and Binomial distributions.
The tools can be classiﬁed into three categories: Singular Enrich-
ment Analysis (SEA), Gene set enrichment analysis (GSEA) and
Modular enrichment analysis (MEA) depending whether the user
preselects or not a list of genes by applying a p-value and fold
change cutoff [25]. More recently developed tools such as CAMERA
[26] and QuSAGE [27] rely on gene permutation and attempt to ac-
count for gene-gene correlation. However, to the best of our
knowledge, none of the currently existing tool provides any correc-
tion for the frequency distribution skewness, which is dealt with
here using the ZE test.
Finally, since the ZE test does not require quantiﬁcation of
items, it is adequate and reliable for applications such as proteo-
mics, genome wide association studies, genome-wide short hairpin
RNA screens or cancer genome sequencing, inter alia. With exper-
imentally validated lists of genes mutated in cancer, the ZE testandom assay, sampled without replacement and unequal probability, to the actual
with 2, 4, 6, 8, and 10 strata neg-log p-values by dots of increasingly lighter gray. (b)
E and ZE under nine conditions: – A/A (actual assay and actual database): The ZE
ys declared signiﬁcant by the test. When comparing the orderings of pathways by
crepancies: the most signiﬁcant pathways are detected by both methods. – A/E, E/E,
e lists, with a good KS distance between neg-log p-values and the exponential
s of the FE test. – E/A, E/U (equal probability sampled assay): the FE test tends to
A/U, U/U, U/A (unequal probability sampled assay or database): for the FE test, the
ZE procedure corrects this in all cases: the ﬁt between neg-log p-values and the
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whereas with an experimentally invalidated list of genes, it refuted
signiﬁcance to most interpretations accredited by the FE test (Sup-
plemental Fig. 3).
4. Conclusion
In conclusion, the skewness of gene frequency distribution in
biological databases renders FE-based gene set enrichment algo-
rithms highly prone to produce false-positive biological interpreta-
tion, an increasingly critical concern at the genomic era [28]. By
avoiding this ﬂaw, stratiﬁed ZE testing has the potential to improve
interpretation of transcriptomes, proteomes, and possibly of other
ﬁelds of biomedical research. Use of the ZE test allows more reli-
able interpretation of lists of genes drawn from studies that are
not solely based on expression levels. Hence, list of disease-predis-
posing genes such as those obtained from single nucleotide poly-
morphism proﬁling or genome-wide association studies can
reliably beneﬁt from GSEA based on ZE statistics. Proteome analy-
sis often yields experimental lists of proteins corresponding to cell
compartments or pathophysiological signatures to be identiﬁed.
More reliable interpretation of these proteins lists will also rely
upon use of the ZE test instead of that of the FE-based assays.
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